Earnings ·
Mereo BioPharma Group plc reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared to…
MREOMereo BioPharma Group plc
Mereo BioPharma Group plc reported a net loss of $7.0 million for the second quarter ended June 30, 2026, compared to $14.6 million in the prior year period, driven by reduced R&D and G&A expenses. The company entered into an option and license agreement with Sentynl Therapeutics for alvelestat, potentially yielding up to $475 million in payments upon exercise. Mereo updated its cash runway guidance, stating that $30.1 million in cash as of June 30, 2026, is expected to fund operations into late-2027. Additionally, the company and partner Ultragenyx are engaging with regulators regarding setrusumab for osteogenesis imperfecta, with further updates expected by year-end 2026. Mereo BioPharma Group plc operates in the biopharmaceutical industry, developing innovative therapeutics for rare diseases.